Jefferies Financial Group restated their hold rating on shares of AstraZeneca (LON:AZN) in a research note published on Friday. Jefferies Financial Group currently has a GBX 5,800 ($75.79) price objective on the biopharmaceutical company’s stock.
Several other brokerages have also commented on AZN. JPMorgan Chase & Co. set a GBX 6,500 ($84.93) price objective on shares of AstraZeneca and gave the stock a buy rating in a report on Tuesday, September 18th. Kepler Capital Markets raised their price objective on shares of AstraZeneca from GBX 5,630 ($73.57) to GBX 6,100 ($79.71) and gave the stock a buy rating in a report on Friday, September 7th. Deutsche Bank restated a buy rating and issued a GBX 6,000 ($78.40) price objective on shares of AstraZeneca in a report on Friday, July 27th. Credit Suisse Group set a GBX 6,350 ($82.97) price objective on shares of AstraZeneca and gave the stock a buy rating in a report on Thursday, August 30th. Finally, UBS Group set a GBX 5,600 ($73.17) price objective on shares of AstraZeneca and gave the stock a neutral rating in a report on Monday, June 25th. Three equities research analysts have rated the stock with a sell rating, seven have issued a hold rating and thirteen have issued a buy rating to the company. AstraZeneca has a consensus rating of Hold and an average target price of GBX 5,700.70 ($74.49).
AZN traded down GBX 70 ($0.91) on Friday, hitting GBX 5,546 ($72.47). The company had a trading volume of 2,077,869 shares, compared to its average volume of 2,310,000. AstraZeneca has a 52-week low of GBX 4,260 ($55.66) and a 52-week high of GBX 5,520 ($72.13).
AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.
Featured Story: Why do companies issue stock splits?
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.